InsiderClue
Stocks · Health care · Pharmaceutical Preparations

ArriVent BioPharma, Inc.

AVBP Clue Score29
United States Fiscal year ends December CIK 0001868279
$16.73 +0.12% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $16.73 −20.82% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 26 Jan 2024. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2023Operating income−74.6Net income−69.3EPS, diluted−32.38Fiscal year 2024Operating income−94.3Net income−80.5EPS, diluted−2.56Fiscal year 2025Operating income−177.5Net income−166.3EPS, diluted−4.32
FY2023FY2024FY2025
Operating income −74.6 −94.3 −177.5
Net income −69.3 −80.5 −166.3
Growth
EPS, diluted −32.38 −2.56 −4.32

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flow
Fiscal year 2023Operating cash flow−55.8Fiscal year 2024Operating cash flow−70.2Fiscal year 2025Operating cash flow−160.6
FY2023FY2024FY2025
Operating cash flow −55.8 −70.2 −160.6

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2023Cash150.4Shareholders’ equity−153.2Fiscal year 2024Cash74.3Shareholders’ equity257.7Fiscal year 2025Cash45.5Shareholders’ equity307.2
FY2023FY2024FY2025
Cash 150.4 74.3 45.5
Shareholders’ equity −153.2 257.7 307.2

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Cash flow

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Operations
−55.8 −70.2 −160.6
Growth
n/a n/a −3.0
Investment
n/a −192.5 −71.2
Financing
42.9 186.6 203.1

Capital expenditure, dividends and buybacks are shown as money out, so negative.